163 related articles for article (PubMed ID: 32996176)
1. Metabolic and hormonal side effects of mitotane treatment for adrenocortical carcinoma: A retrospective study in 50 Danish patients.
Vikner ME; Krogh J; Daugaard G; Andreassen M
Clin Endocrinol (Oxf); 2021 Feb; 94(2):141-149. PubMed ID: 32996176
[TBL] [Abstract][Full Text] [Related]
2. Mitotane treatment in patients with adrenocortical cancer causes central hypothyroidism.
Russo M; Scollo C; Pellegriti G; Cotta OR; Squatrito S; Frasca F; Cannavò S; Gullo D
Clin Endocrinol (Oxf); 2016 Apr; 84(4):614-9. PubMed ID: 26221968
[TBL] [Abstract][Full Text] [Related]
3. Central Hypothyroidism is Frequent During Mitotane Therapy in Adrenocortical Cancer Patients: Prevalence and Timeline.
Poirier J; Godemel S; Mourot A; Grunenwald S; Olney HJ; Le XK; Lacroix A; Caron P; Bourdeau I
J Clin Endocrinol Metab; 2023 Aug; 108(9):2336-2342. PubMed ID: 36856782
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of mitotane in the treatment of adrenocortical carcinoma: A retrospective study in 34 Belgian patients.
Maiter D; Bex M; Vroonen L; T'Sjoen G; Gil T; Banh C; Chadarevian R
Ann Endocrinol (Paris); 2016 Oct; 77(5):578-585. PubMed ID: 27063476
[TBL] [Abstract][Full Text] [Related]
5. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection.
Terzolo M; Baudin AE; Ardito A; Kroiss M; Leboulleux S; Daffara F; Perotti P; Feelders RA; deVries JH; Zaggia B; De Francia S; Volante M; Haak HR; Allolio B; Al Ghuzlan A; Fassnacht M; Berruti A
Eur J Endocrinol; 2013 Sep; 169(3):263-70. PubMed ID: 23704714
[TBL] [Abstract][Full Text] [Related]
6. Androgen serum levels in male patients with adrenocortical carcinoma given mitotane therapy: A single center retrospective longitudinal study.
Delbarba A; Cosentini D; Facondo P; Laganà M; Pezzaioli LC; Cremaschi V; Alberti A; Grisanti S; Cappelli C; Ferlin A; Berruti A
Front Endocrinol (Lausanne); 2023; 14():1128061. PubMed ID: 37077359
[TBL] [Abstract][Full Text] [Related]
7. [Mitotane in the treatment of adrenal carcinoma].
Sane T
Duodecim; 2010; 126(17):2040-6. PubMed ID: 21053521
[TBL] [Abstract][Full Text] [Related]
8. Hypogonadism and sexual function in men affected by adrenocortical carcinoma under mitotane therapy.
Canu L; Sparano C; Naletto L; De Filpo G; Cantini G; Rapizzi E; Martinelli S; Ercolino T; Cioppi F; Fantoni A; Zanatta L; Terreni A; Mannelli M; Luconi M; Maggi M; Lotti F
Front Endocrinol (Lausanne); 2023; 14():1320722. PubMed ID: 38269251
[TBL] [Abstract][Full Text] [Related]
9. Mitotane-induced dyspnoea: an unusual side effect.
Farooq AU; Amjad W; Kochar T; Adhikari S
BMJ Case Rep; 2018 Sep; 2018():. PubMed ID: 30173131
[TBL] [Abstract][Full Text] [Related]
10. Recovery of adrenal function after stopping mitotane in patients with adrenocortical carcinoma.
Altieri B; Kimpel O; Megerle F; Detomas M; Chifu I; Fuss CT; Quinkler M; Kroiss M; Fassnacht M
Eur J Endocrinol; 2024 Feb; 190(2):139-150. PubMed ID: 38244214
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant mitotane treatment for adrenocortical carcinoma.
Terzolo M; Angeli A; Fassnacht M; Daffara F; Tauchmanova L; Conton PA; Rossetto R; Buci L; Sperone P; Grossrubatscher E; Reimondo G; Bollito E; Papotti M; Saeger W; Hahner S; Koschker AC; Arvat E; Ambrosi B; Loli P; Lombardi G; Mannelli M; Bruzzi P; Mantero F; Allolio B; Dogliotti L; Berruti A
N Engl J Med; 2007 Jun; 356(23):2372-80. PubMed ID: 17554118
[TBL] [Abstract][Full Text] [Related]
12. Changes in total and acylated ghrelin levels during mitotane treatment in patients with adrenocortical carcinoma.
Komarowska H; Ruciński M; Fichna M; Bromińska B; Iżycki D; Czarnywojtek A; Ruchała M
Pol Arch Intern Med; 2019 Aug; 129(7-8):469-475. PubMed ID: 31169262
[TBL] [Abstract][Full Text] [Related]
13. Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma.
Kerkhofs TM; Baudin E; Terzolo M; Allolio B; Chadarevian R; Mueller HH; Skogseid B; Leboulleux S; Mantero F; Haak HR; Fassnacht M
J Clin Endocrinol Metab; 2013 Dec; 98(12):4759-67. PubMed ID: 24057287
[TBL] [Abstract][Full Text] [Related]
14. High-Dose Mitotane-Induced Encephalopathy in the Treatment of Adrenocortical Carcinoma.
Pape E; Feliu C; Yéléhé-Okouma M; Colling N; Djerada Z; Gambier N; Weryha G; Scala-Bertola J
Oncologist; 2018 Mar; 23(3):389-390. PubMed ID: 29192018
[No Abstract] [Full Text] [Related]
15. Ovarian cyst formation in women of reproductive age receiving mitotane as part of the treatment of adrenocortical carcinoma: Clinical and experimental observations.
Abrahamsson G; Ekerhovd E; Janson PO; Jansson S; Ahlman H; Wängberg B; Norström A
Acta Obstet Gynecol Scand; 2020 Oct; 99(10):1297-1302. PubMed ID: 32282928
[TBL] [Abstract][Full Text] [Related]
16. High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up.
Mauclère-Denost S; Leboulleux S; Borget I; Paci A; Young J; Al Ghuzlan A; Deandreis D; Drouard L; Tabarin A; Chanson P; Schlumberger M; Baudin E
Eur J Endocrinol; 2012 Feb; 166(2):261-8. PubMed ID: 22048971
[TBL] [Abstract][Full Text] [Related]
17. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement.
Chortis V; Taylor AE; Schneider P; Tomlinson JW; Hughes BA; O'Neil DM; Libé R; Allolio B; Bertagna X; Bertherat J; Beuschlein F; Fassnacht M; Karavitaki N; Mannelli M; Mantero F; Opocher G; Porfiri E; Quinkler M; Sherlock M; Terzolo M; Nightingale P; Shackleton CH; Stewart PM; Hahner S; Arlt W
J Clin Endocrinol Metab; 2013 Jan; 98(1):161-71. PubMed ID: 23162091
[TBL] [Abstract][Full Text] [Related]
18. Effects of mitotane on the hypothalamic-pituitary-adrenal axis in patients with adrenocortical carcinoma.
Reimondo G; Puglisi S; Zaggia B; Basile V; Saba L; Perotti P; De Francia S; Volante M; Zatelli MC; Cannavò S; Terzolo M
Eur J Endocrinol; 2017 Oct; 177(4):361-367. PubMed ID: 28780517
[TBL] [Abstract][Full Text] [Related]
19. Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma.
Hescot S; Seck A; Guerin M; Cockenpot F; Huby T; Broutin S; Young J; Paci A; Baudin E; Lombès M
J Clin Endocrinol Metab; 2015 Aug; 100(8):2890-8. PubMed ID: 26120791
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly.
Daffara F; De Francia S; Reimondo G; Zaggia B; Aroasio E; Porpiglia F; Volante M; Termine A; Di Carlo F; Dogliotti L; Angeli A; Berruti A; Terzolo M
Endocr Relat Cancer; 2008 Dec; 15(4):1043-53. PubMed ID: 18824557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]